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Abstract
Microglia are the resident macrophages of the CNS, which
secrete several pro- and anti-inflammatory cyto-chemokines
including interleukin-1b (IL-1b), in response to pathogenic
stimuli. Once secreted, IL-1b binds to IL-1 receptor present on
microglia and initiates the production of inflammatory cyto-
kines in microglia. However, the detailed information regarding
the molecular mechanisms of IL-1b triggered inflammatory
pathways in microglia is lacking. Our studies focused on the
role of Kr€uppel-like factor 4 (Klf4) in mediating the regulation of
pro-inflammatory gene expression upon IL-1b stimulation in
microglia. Our studies show that stimulation of microglia with
IL-1b robustly induces Klf4 via PI3K/Akt pathway which
positively regulates the production of endogenous IL-1b as
well as other pro-inflammatory markers, cyclooxygenase-2,
monocyte chemoattractant protein-1 and interleukin-6 (IL-6). In
addition, we report that Klf4 negatively regulates the expres-
sion of inducible nitric oxide synthase, thereby playing a key
role in regulating the immunomodulatory activities of microglia.
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Interleukin-1b (IL-1b) is a prominent pro-inflammatory
cytokine, which is expressed at low levels in healthy CNS,
but increases rapidly early in response to stress or pathogenic
invasion of the CNS (Rothwell and Luheshi 2000). IL-1b is
implicated in the progression of chronic neurodegenerative
diseases including Alzheimer’s disease, and Parkinson’s
disease as well as acute neuroinflammatory conditions such
as traumatic brain injury and stroke (Meda et al. 1999;
Rothwell and Luheshi 2000; Halle et al. 2008). In addition,
circulating IL-1b can up-regulate the production of prosta-
glandins and other toxic mediators in the CNS and is therefore
considered as master regulator of neuroinflammation (Saper
and Breder 1992; Basu et al. 2004). Microglia and astrocytes
are the primary source of IL-1b in the CNS (Davies et al.
1999; Toda et al. 2002), and once secreted, it can further
stimulate its own production in an autocrine/paracrine fashion
by binding to its cognate IL-1 receptors (IL-1Rs), primarily IL-
1RI, as membrane bound receptor that belongs to the IL-1
superfamily (McMahan et al. 1991; Rothwell and Luheshi
2000; Toda et al. 2002). This ensures a constitutive produc-
tion of IL-1b by activated microglia which further amplifies
injury signals (Basu et al. 2004). However, themechanisms of
endogenous IL-1b production in microglia in response to
IL-1b are complex and not fully understood. Also, the
production of pro-inflammatory cytokines and pro-inflamma-
tory enzymes including cyclooxygenase-2 (Cox-2) and induc-
ible nitric oxide synthase (iNOS) by microglia in response to
IL-1b has been long debated and existing literature presents
contradictory evidences (Basu et al. 2002; Pinteaux et al.
2002). Therefore, this study was undertaken to investigate the
detailed signatures of IL-1b induced microglial activation.
Previous studies from our lab have shown that microglia
up-regulate the production of Kr€uppel like factor 4 (Klf4), a
zinc finger transcription factor, in response to lipopolysac-
charide (LPS) (Kaushik et al. 2010). In response to LPS,
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Klf4 co-activates iNOS promoter by potentially interacting
with nuclear factor-jB (NF-jB) (p65) in macrophages and
microglia (Feinberg et al. 2005; Kaushik et al. 2010). Effect
of IL-1b has also been studied on the expression of Klf4 in
rat cardiac myocytes where it was reported that IL-1b
regulates Klf2, but it had no effects on the expression of Klf4
(Cullingford et al. 2008). However, literature is lacking on
the role of Klf4 in IL-1b mediated microglial activation.
Therefore we focused on IL-1b mediated Klf4 production in
murine microglia and sought to understand the role of Klf4
on downstream production of key inflammatory markers.
Although, a myeloid specific Klf4 knockdown model has
been described recently (Liao et al. 2011), there are no
known commercially available Klf4 genetic knockout mod-
els as Klf4/ mice do not survive and die shortly after birth
because of defect in epithelial differentiation and barrier
formation (Segre et al. 1999; Katz et al. 2002). Therefore,
Klf4 knockdown and other transfection studies are carried
out mostly in in vitro models of inflammation.
Materials and methods
Cell culture and reagents
Mouse microglial cell line BV-2 was gifted by Dr Steve Levison,
University of Medicine and Dentistry, New Jersey, USA and
maintained as described previously (Kaushik et al. 2010). Primary
microglia were prepared from primary mixed glial cell cultures that
were isolated from P0-P2 mouse brains as described in our previous
studies (Kaushik et al. 2012). Pathway specific inhibitors, U0126
Extracellular signal-regulated kinase (ERK) inhibitor], SB203580
(p38 pathway inhibitor), SP600125 (JNK inhibitor), and LY294002
(PI3K/Akt pathway inhibitors) were procured from Calbiochem
(Millipore, Billerica, MA, USA) and used at a final concentration of
10 lM for 30 min prior to IL-1b treatment. Mouse recombinant IL-
1b (R&D Systems, Minneapolis, MN, USA) was used at a final
concentration of 5 ng/mL for different time points in accordance
with the current literature (Basu et al. 2002).
Animal experiments
Six- to eight-week-old BALB/c mice of either sex were injected
intraperitoneally (i.p.) with 100 lL of 10 ng/g body weight of IL-1b
dissolved in 1X phosphate-buffered saline (PBS) every 24 h for
different durations as described elsewhere (Ogimoto et al. 2006).
Mock-treatment group received the same volume of the carrier (1X
PBS). Groups of three mice were sacrificed at each time point either
for tissue or protein. The animals were procured from the animal
facility of National Brain Research Centre, and all the experiments
were performed according to the protocol approved by the
Institutional Animal Ethics Committee vide protocol no. NBRC/
IAEC/2013/77 and NBRC/IAEC/2011/62. All the animal research
was done in compliance with the ARRIVE guidelines.
Immunoblotting
Mock-treated and IL-1b treated BV-2 cells were harvested for the
isolation of total, cytoplasmic and nuclear extracts as described
previously (Kaushik et al. 2010). Whole brain homogenates from
IL-1b and mock-treated mice were prepared for total protein for in
vivo studies. The proteins were subjected to western blot analysis to
measure their levels and primary antibodies against Klf4 (1 : 500),
iNOS and Cox-2 (1 : 1000; Millipore); pNF-jB (Ser536), pAkt
(Ser473), total Akt, pERK (Thr202/Tyr204), total ERK (1 : 1000;
Cell Signaling technology, Beverly, MA, USA), total NF-jB
(1 : 1000; Santa Cruz biotechnology, Santa Cruz, CA, USA) and
IL-1b (1 : 500; R&D Systems) were used. The images were
captured using the Genesnap software from Syngene (Syngene,
Cambridge, UK). The blots were stripped and re-probed either with
anti b-actin (1 : 10 000; Sigma Aldrich, St. Louis, MO, USA) or
C23 (nucleolin) antibodies (1 : 1000; Santa Cruz biotechnology)
and the protein levels were normalized to b-actin or C23.
Immunocytochemistry
Primary mouse microglia cells were stained with rabbit anti-Klf4
antibody (1 : 250;Millipore) overnight at 4°C.After PBSwashes, the
anti-rabbit fluorescein isothiocyanate (FITC) conjugated secondary
antibody (1 : 250; Vector Laboratories, Burlingame, CA, USA) was
added for 1.5 h and then mounted with mounting medium containing
4,6-diamidino-2-phenylindole (Vector Laboratories). Images were
captured using Zeiss apotome microscope (Carl Zeiss MicroImaging
GmbH, Göttingen Germany; magnification 920; Scale bar 20 lm).
Immunohistochemistry
IL-1b treated and age-matched mock-treated BALB/c mice were
perfused, and the brains were fixed and processed for cryostat
sectioning as described elsewhere (Kaushik et al. 2010). Anti-Iba1
antibody (1 : 250; cat. MABN92; Millipore) and rabbit anti-Klf4
(1 : 100; Millipore) were used for double labeling of microglia.
Similarly, astrocytes and neurons were also double labeled with
Klf4 along with mouse anti-glial fibrillary acidic protein (GFAP)
(1 : 200; Millipore), and mouse anti-bIII-tubulin antibody (1 : 200;
Cell signaling technologies), respectively. After five washes with 1X
PBS, the sections were incubated with anti-mouse Alexa Fluor 594
(1 : 1000; Molecular Probes, Eugene, OR, USA) for Iba1, GFAP
and bIII-tubulin and anti-rabbit FITC (1 : 250; Vector Laboratories)
for Klf4 for additional 1.5 h. The slides were then mounted with
medium containing 4,6-diamidino-2-phenylindole (Vector laborato-
ries). Images were captured using Zeiss apotome fluorescence
microscope (Zeiss, Germany; magnification 940; Scale bar 50 lm).
Quantitative real-time PCR (qRT-PCR)
qRT-PCR using PowerSYBR Green (Applied Biosystems, Foster
city, CA, USA) was performed on ABI Prism 7500 sequence
detection system (Applied Biosystems) as described previously
(Kaushik et al. 2012). Oligonucleotide primers specific for different
genes were procured from Sigma (Sigma Aldrich) and listed in
Table S1. The conditions used for real-time PCR were as follows:
95°C for 3 min (1 cycle), 40 cycles of (94°C for 20 s, 60°C for 30 s,
and 72°C for 40 s). The results were analyzed using the iCycler
Thermal Cycler Software (Applied Biosystems) and normalized
with those from 18S rRNA internal control and quantified using
comparative Ct (2
[Δ][Δ]Ct) method.
Cytokine bead array
The cytokine bead array kit (mouse inflammation cytokine bead
array kit; BD Biosciences, Franklin Lakes, NJ, USA) was used to
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quantitatively measure cytokine levels in the control and IL-1b
treated BV-2 cells. The assay was performed according to the
manufacturer’s instructions and analyzed on the FACS Calibur (BD
Biosciences) as described previously (Ghoshal et al. 2007).
Site-directed mutagenesis
Site-directed mutagenesis (SDM) was carried out using QuikChange
SDM kit procured from Stratagene (Stratagene, La Jolla, CA, USA)
according to the manufacturer’s protocol. The sequence of double
stranded primer designed for site-directed mutagenesis at 212 bp
on iNOS promoter in iNOS/pGL2 luciferase construct is as follows:
5′-CTA CGT GCT GCC TAG TGT CCA CTG CCT TGG ACG-3′.
Generation of K-10 (pcDNA3.1-Klf4) construct
Oligonucleotide primers were designed to amplify the coding
sequence of full length mouse Klf4 cDNA that yielded a 1452 bp
(1.4 kb) product. The sequences of the oligonucleotide primers used
for cloning is as follows: forward primer: 5′-ATG AGG CAG CCA
CCT GGC GA-3′; reverse primer: 5′-TTA AAA GTG CCT CTT
CAT GTG TAA-3′. The amplified product was inserted into the
pcDNA3.1/V5 His TopoTA expression vector (kindly gifted by Dr
Nihar Ranjan Jana, National Brain Research Centre, Manesar,
Haryana, India) and ligated to generate pcDNA3.1-Klf4 (K-10)
construct. The construct was then sequenced commercially (ILS
Bioservices, Manesar, Haryana, India).
Transfection studies
Short interfering RNA (siRNA) against mouse Klf4, siKlf401
(sense: 5′-CGG AGU UGG ACC CAG UAU A-3′) was procured
from Sigma Aldrich, siKlf402 (sense: 5′-UCC AAA GAA GAA
GGA UCU CUU-3′) and scrambled siRNA (scRNA) (sense: 5′-
GUG CAC AUG AGU GAG AU UU-3′) were procured from
Dharmacon RNAi technologies (Thermo fisher Scientific, Waltham,
MA,USA). 100 nM of siRNA and scRNA were used for transfec-
tion using lipofectamine RNAi max (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. For over-expression
studies, BV-2 cells were transfected with K-10 (pcDNA3.1-Klf4)
and pcDNA3.1-LacZ constructs using lipofectamine 2000 (Invitro-
gen) as described previously (Kaushik et al. 2012).
Luciferase assay
Luciferase reporter gene constructs, iNOS/pGL2 (kindly provided
by Dr Mark W. Feinberg and Dr Mukesh K. Jain, Harvard Medical
School, Boston, Massachusetts, USA; originally constructed by Dr
Mark Perella) (Perrella et al. 1996), 212ΔiNOS/pGL2 (SDM
mutated iNOS/pGL2) and pCOX301 (a kind gift from Dr
Manikuntala Kundu, Bose Institute, Kolkata, India) (Pathak et al.
2004), were used for promoter binding assays. After 24 h of
transfection of BV-2 cells with either Klf4-SiRNA or K-10 construct
(pcDNA3.1-Klf4), 1 lg each of luciferase reporter constructs were
transfected using 5 lL of lipofectamine 2000 (Invitrogen) in Opti-
MEM for additional 24 h before IL-1b treatment.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using Chip-IT express kit according to
manufacturer’s protocol (Active motif, Carlsbad, CA, USA) as
described earlier (Caretti et al. 2003). Sheared chromatin was
incubated with 2 lg of mouse anti-Klf4 Transcruze antibody (Santa
Cruz biotechnology) or 2 lg of rabbit IgG (Abcam, Cambridge, MA,
USA). Input (1 : 10 dilution) and ChIP DNA were analyzed using a
thermocycler (Applied biosystems) with the following program:
94°C for 3 min; 36 cycles of (94°C for 20 s, 59°C for 30 s and 72°C
for 30 s); hold cycle at 10°C. DEPC H2O was added to water only
control. The primers on IL-1b promoter used for ChIP reactions
which generated 111 bp amplicon (99 bp to +10 bp) are as
follows: forward: 5′- TCA GTT TTG TTG TGA AAT CAG T – 3′,
reverse: 5′- CAG GGT TTG TTG TCC AAC TT- 3′.
Statistical analysis
All the experiments were performed in sets of three unless otherwise
mentioned and the data generated were analyzed statistically by
paired two-tailed Student’s t-test. A statistical p value < 0.01 and
0.05 were considered significant.
Results
IL-1b induces neuroinflammation and Klf4 up-regulation in
microglia in vivo
To find out if IL-1b increased the levels of Klf4 in murine
brains, we performed immunoblotting of the brain homo-
genates from cytokine treated and mock-treated animals. We
observed a significant increase in the levels of Klf4 by about
1.5-fold and 2-fold after 3 and 5 days of IL-1b injections,
respectively as compared to mock-treated mice brain
(Fig. 1a). We also observed twofold increase in the phos-
phorylation of NF-jB in the brains of mice after 5 days of
IL-1b injection (Fig. 1a). In addition, qRT-PCR analysis of
Klf4 showed a significant increase in the transcripts of Klf4,
iNOS and Cox-2 gene within 5 days of IL-1b treatment as
compared to mock-treated group (Fig. 1b).
Furthermore, using double-immunostaining, we observed
that within 3 days after injection of the cytokine, microglial
cells exhibited a transformation from ‘resting’ state, with
basal levels of Iba1 expression (control, upper panel; arrow)
to an ‘activated’ (ameboid) state with increased Iba1
expression (lower panels, 3 day and 5 day treatment groups;
arrows) (Fig. 1c; Figure S1a). In addition, expression of Klf4
increased significantly after 3 and 5 days of IL-1b injection
in these cells as witnessed by co-localization of Klf4 (green)
with Iba1 (red) (merged images; Fig. 1c; Figure S1a).
Furthermore, we observed that while astrocytes (GFAP +ve
cells) did not express Klf4 (Fig. 1d; Figure S1b), neurons
(bIII-tubulin +ve cells) expressed Klf4 at basal levels
(Fig. 1e; Figure S1c). However, no changes in the levels of
Klf4 were observed either in astrocytes or neurons even after
5 days of IL-1b injection. Overall, our findings show for the
first time that IL-1b stimulates microglial activation along
with an up-regulation of Klf4 in microglia.
IL-1b stimulates Klf4 up-regulation and nuclear
translocation in microglia in vitro
In primary microglia, we observed that with respect to mock-
treated cells (upper panel), Klf4 staining intensity increased
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within 1 h of IL-1b treatment, and that it is localized within
the nuclei as shown by the arrows (lower panel; FITC,
green) (Fig. 2a). We also carried out time-dependent stim-
ulation of BV-2 microglia with IL-1b and found that it
resulted in increased expression of total Klf4 protein within
1 h of stimulation (Fig. 2b). In addition, we measured the
levels of Klf4 from cytoplasmic/nuclear extractions isolated
from BV-2 microglia that were stimulated with IL-1b for
different durations of 5, 15, 30, 45 or 60 min. Expression of
Klf4 increased gradually in the cytoplasmic extracts after
30 min of IL-1b stimulation and reached about 2-fold with
respect to untreated control condition after 60 min of
treatment (Fig. 2c; CE). However, Klf4 translocated to
nuclei as early as 5 min and remained at significantly higher
levels after 15 min of IL-1b stimulation (Fig. 2c; NE). We
also observed a considerable twofold increase in phosphor-
ylation of NF-jB within 1 h of IL-1b stimulation of BV-2
cells (Fig. 2d).
IL-1b induces the phosphorylation of ERK and Akt, and
PI3K/Akt pathway plays a crucial role in determining Klf4
expression
Although there are reports of IL-1b induced ERK activation
in mixed glial cells (McNamee et al. 2010), there is
conflicting information on the role of interleukin-1 in
mediating the activation of ERK or PI3K/Akt pathways in
microglia. However, we observed significant phosphoryla-
tion of both Akt and ERK pathways in IL-1b stimulated
microglia (Fig. 3a and b). Also, we found that within
45 min of IL-1b stimulation, the levels of ERK decreased
significantly which may be because of the negative feedback
by several mechanisms including direct activation of MAPK
phosphatases by p42 and p44 MAPK (Brondello et al.
1999; Peng et al. 2010). The levels of ERK phosphorylation
were again found to be increased after 60 min of IL-1b
stimulation. Similar observations regarding ERK phosphor-
ylation were made by another study on BV-2 cells in
response to a mixture of different cytokines (Sheng et al.
2011).
Furthermore, to find out if either of these pathways is
crucial for Klf4 up-regulation in IL-1b mediated microglial
activation, we incubated microglia with specific inhibitors of
ERK or PI3K/Akt pathways for 30 min prior to 1 h of IL-1b
stimulation. The specificity of inhibition was confirmed by
significant decrease in phosphorylation of ERK and Akt in
unstimulated and IL-1b stimulated cells in presence of ERK
(U0126) and PI3K/Akt (LY294002) inhibitors, respectively
(Figure S2). Interestingly, we observed a significant up-
regulation of Akt phosphorylation upon ERK inhibition in
both unstimulated and IL-1b stimulated conditions. This
Fig. 1 IL-1b induces Kr€uppel like factor-4 (Klf4) expression in mice
brain. 6- to 8-week-old BALB/c mice were injected with 10 ng/g body
weight of IL-1b i.p. for different days. (a) Immunoblot analysis of Klf4
and pNF-jB from mice brains after 3 and 5 days of IL-1b treatment.
Graph represents fold change in the levels of Klf4 and pNF-jB with
respect to control. The levels of pNF-jB were normalized to total NF-
jB and Klf4 levels were normalized to b-actin. (b) qRT-PCR analysis of
inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (Cox-2) and
Klf4 transcript levels relative to mock-treated condition after different
time durations. Values were normalized to 18S rRNA levels. (c) Double
staining with anti-Klf4 (green) and anti-Iba1 (red) antibody. (d and e)
Double staining for the expression of Klf4 (green) in (d) GFAP +ve (red)
astrocytes and (e) bIII-tubulin +ve (red) neurons. Nuclei were stained
with 4,6-diamidino-2-phenylindole (DAPI) (blue) and images were
captured using Zeiss apotome fluorescence microscope (Scale bar-
50 lm; magnification-409 ). Data represent mean  SEM from three
animals in each group. *Statistical difference in comparison to mock-
treated condition (p < 0.05).
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phenomenon has already been reported in a number of
studies which suggest that inhibition of ERK leads to the
phosphorylation of Akt at Ser473 by a possible feedback
regulation in different types of cancer cells and macrophages
(Luyendyk et al. 2008; Chen et al. 2012; Turke et al. 2012).
We observed that IL-1b failed to increase Klf4 levels in cells
pre-treated with LY294002, as compared to cells treated with
IL-1b alone, highlighting the role of PI3K/Akt signaling in
IL-1b mediated Klf4 up-regulation (Fig. 3c). In contrast,
ERK inhibition by U0126 did not lead to any significant
changes in Klf4 levels in response to IL-1b stimulation. We
also observed a modest increase in Klf4 levels in control cells
treated with U0126, which might be a consequence of
enhanced Akt signaling with ERK inhibition.
Klf4 is crucial for Cox-2 up-regulation in IL-1b stimulated
microglia
We also measured a significant increase in Cox-2 expression
in response to IL-1b in vitro (Fig. 4a and b). To study if Klf4
regulated the production of Cox-2, we carried out knock-
down of Klf4. To assess transfection efficiency and speci-
ficity of knockdown, we used two different siRNAs,
siKlf401 and siKlf402 that targeted Klf4 transcript at
different regions, and carried out qRT-PCR for Klf4 as well
as for Klf2, a closely related transcription factor. We
observed that while siKlf401 offered more than 50%
knockdown, siKlf402 showed about 35% knockdown of
Klf4 mRNA in unstimulated as well as IL-1b stimulated
BV-2 cells. Also, none of the siRNAs showed any off-target
Fig. 2 IL-1b up-regulates the production of
total Kr€uppel like factor-4 (Klf4) and
increases its nuclear translocation in vitro.
Primarymicroglia andBV-2murinemicroglia
cells were treated with IL-1b at a
concentration of 5 ng/mL for different
durations. (a) Images showing the staining
for Klf4 [fluorescein isothiocynate(FITC);
green], 4,6-diamidino-2-phenylindole (DAPI)
(blue) and merged images (Klf4 + DAPI).
Klf4 expression increases in IL-1b treated
primary microglia as compared to untreated
control cells as shown by the arrows. Images
were captured using Zeiss apotome fluo-
rescence microscope (Scale bar-20 lm;
magnification-20X). (b) Immunoblotting for
Klf4 from total protein isolated from BV-2
cells treated with IL-1b. (c) Immunoblotting
for cytoplasmic (CE) and nuclear (NE) Klf4
from BV-2 cells treated with IL-1b. (d)
Immunoblot analysis of pNF-jB after 1 h of
IL-1b treatment. Klf4 protein levels were
normalized to b-actin and C23; pNF-jB
levels were normalized to total NF-jB
levels. Klf4 mRNA was normalized to 18S
rRNA. The graphs represent fold change
in normalized Klf4 mRNA and protein
levels at various time points with respect to
mock-treated cells. Data represent mean 
SEM from three independent experiments.
*, ** Statistical differences in comparison to
mock-treated condition (*p < 0.05;
**p < 0.01).
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effects as measured by the levels of Klf2, which remained
unaltered (Fig. 4c). Therefore, we used siKlf401 (hereafter
referred to as ‘siKlf4’) for the rest of the experiments, owing
to its better knockdown efficiency over siKlf402. We found
that siRNA mediated knockdown of Klf4 resulted in
significant reduction in Cox-2 protein levels in IL-1b
stimulated BV-2 microglia suggesting that Klf4 is crucial
for Cox-2 production (Fig. 4d).
Klf4 negatively regulates iNOS expression in microglia
We then wanted to find if IL-1b up-regulated iNOS, and
whether Klf4 was responsible for its up-regulation. In
contrast to many existing studies (Tsujino et al. 1994; Wong
et al. 1996; Ravichandran et al. 2011), we found that in
response to IL-1b, iNOS protein levels were not altered when
compared with mock-treated condition (Fig. 5a). Further-
more, there were no changes in iNOS mRNA levels even
after 12 h of IL-1b treatment in microglia in vitro (Fig. 5b),
suggesting that transcriptional regulation of iNOS is lacking.
We then analyzed iNOS mRNA and protein levels upon Klf4
knockdown in BV-2 cells after IL-1b treatment. Interest-
ingly, we observed that both iNOS transcript and protein
levels were significantly up-regulated in siKlf4 alone as well
as in siKlf4 + IL-1b treatment condition with respect to
IL-1b alone condition (Fig. 5c and d), suggesting that Klf4 is
highly critical for regulating both, basal expression of iNOS
as well as its levels in response to IL-1b.
To further validate the role of Klf4 in down-regulation of
iNOS, we transfected BV-2 cells with K-10 construct which
over-expressed Klf4 (Klf4-pcDNA3.1). We also transfected
the cells with LacZ construct (pcDNA3.1), which was used
as a control. We observed that Klf4 over-expression was
associated with a significant decrease in iNOS protein levels
in both, mock-treated cells and in response to IL-1b
treatment as compared to LacZ + IL-1b condition (Fig. 6a).
Furthermore, to assess iNOS promoter activity upon Klf4
over-expression, we carried out transfection with iNOS
promoter-luciferase construct (iNOS/pGL2) and co-transfect-
ed the cells with either K-10 or LacZ constructs. We
observed that upon Klf4 over-expression in unstimulated
microglial cells (K-10 alone), iNOS promoter activity was
significantly reduced by more than twofold, as measured by
decrease in relative luciferase activity with respect to LacZ
condition (Fig. 6b). IL-1b stimulation in K-10 transfected
cells potentiated this decrease in iNOS promoter activity,
further strengthening the role of Klf4 in negative regulation
Fig. 3 PI3K/Akt pathway is crucial for the
expression of Kr€uppel like factor-4 (Klf4) in
IL-1b stimulated microglia. (a) Immunoblot
analysis of phospho and total Akt upon
IL-1b stimulation. Graph represents fold
change in pAkt/Akt levels over mock-
treated cells. (b) Immunoblot analysis of
phospho and total ERK after IL-1b
treatment. Graph represents fold change
in pERK/ERK levels over mock-treated
condition. Values for pERK and pAkt were
normalized with total ERK and total Akt,
respectively. (c) Immunoblot analysis of Klf4
from BV-2 cells incubated for 30 mins with
pathway specific inhibitors (U0126, ERK
inh; LY294002, PI3K inh), prior to 1 h of
treatment with IL-1b. Graph represents fold
change in Klf4 protein levels with respect to
mock-treated cells. Klf4 values were
normalized to b-actin; Data represent
mean  SEM from three independent
experiments. *, ** Statistical differences in
comparison to mock-treated condition
(*p < 0.05; **p < 0.01); ## statistical
difference with respect to IL-1b treated
condition (##p < 0.01).
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of basal iNOS expression by probably interacting with its
promoter element.
Klf4 decreases iNOS promoter activity in response to IL-1b
To confirm if direct Klf4 binding was required for down-
regulating iNOS promoter activity, we mutated the Klf4
binding site at 212 bp position by carrying out site-directed
mutagenesis of iNOS/pGL2 to make a mutated construct,
212ΔiNOS/pGL2 and transfected BV-2 microglia using
these constructs. We found that while iNOS/pGL2 promoter
activity did not increase upon IL-1b stimulation, transfection
with 212ΔiNOS/pGL2 construct significantly increased the
promoter activity in response to 3 h of IL-1b treatment
(Fig. 6c). We observed more than twofold increase in iNOS
promoter activities in BV-2 cells in 212ΔiNOS/
pGL2 + IL-1b condition with respect to iNOS/pGL2 trans-
fected cells or iNOS/pGL2 + IL-1b condition. These find-
ings confirmed that Klf4 negatively regulated iNOS promoter
activity.
IL-1b stimulates the production of MCP-1 and IL-6 via Klf4
We also sought to confirm whether IL-1b up-regulated pro-
inflammatory cyto-chemokines in BV-2 murine microglia.
We observed considerable increase in the levels of both,
monocyte chemoattractant protein-1 (MCP-1) and IL-6 upon
IL-1b stimulation with respect to control untreated conditions
(Figure S3a and b). In addition, we observed remarkable
decrease in the levels of both these cytokines after 3 h of
IL-1b stimulation (Figure S3a and b). These findings suggest
that while IL-1b potentially up-regulated both MCP-1 and
IL-6 in microglia, this pathway is tightly regulated, especially
during the early response phase.
Since our earlier studies showed that Klf4 played an
important role in mediating the up-regulation of these cyto-
chemokines in response to LPS (Kaushik et al. 2010), we
were interested in understanding the role of Klf4 in
regulating these cytokines in response to IL-1b. We found
that after 6 h of IL-1b stimulation, knockdown of Klf4
resulted in a significant decrease in the levels of both these
cytokines by approximately 2-fold with respect to IL-1b
treatment group (Figure S3c). Similarly, after 12 h of IL-1b
stimulation, IL-6 levels were found to be significantly
reduced in Klf4 knockdown condition as compared to
IL-1b condition (Figure S3d). Also, we observed a signif-
icant reduction in the levels of MCP-1 in siKlf4 + IL-1b
condition with respect to IL-1b alone condition, as well as in
Fig. 4 Kr€uppel like factor-4 (Klf4) is critical
for IL-1b mediated induction of
cyclooxygenase-2 (Cox-2) in vitro. (a)
Immunoblot analysis of Cox-2 protein in
IL-1b treated and mock-treated conditions.
Graph represents fold change in Cox-2
protein levels with respect to control. (b)
Graph showing qRT-PCR analysis of Cox-2
mRNA in response to IL-1b treatment and is
represented as fold change over control. (c)
Graph representing Klf4 and Klf2 mRNA
levels showing knockdown efficiency and
specificity of different siRNAs (siKlf401 and
siKlf402). (d) Immunoblot analysis of Cox-2
and Klf4 expression in IL-1b stimulated and
unstimulated BV-2 cells transfected with
either 100 nM of siKlf4 (siKlf401) or scRNA.
Graph represents fold change in Cox-2 and
Klf4 levels over mock-treated condition.
Values were normalized to b-actin. Data
represent mean  SEM from three
independent experiments. *, ** Statistical
differences in comparison to mock-
treated condition (*p < 0.05, **p < 0.01);
## statistical difference with respect to IL-
1b treated condition (##p < 0.01).
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siKlf4-alone condition with respect to mock-treated condi-
tions (Figure S3d). This suggested that Klf4 potentially
regulated the basal level expression of pro-inflammatory
cytokines and also significantly influenced their up-regula-
tion in response to IL-1b.
IL-1b stimulates production of endogenous IL-1b by
interaction of Klf4 with IL-1b promoter
The evidences in favor of endogenous IL-1b production in
response to IL-1b treatment are contradictory. We observed
that while mature IL-1b is increased in total cellular extracts
after 6 h of IL-1b treatment, significant amounts of mature
IL-1b were detected in supernatants after 1 h of cytokine
stimulation which continued to be significant until 6 h after
the treatment (Fig. 7a). Similarly, IL-1b mRNA levels were
also found to be significantly up-regulated after 1 and 3 h of
IL-1b treatment (Fig. 7b). In one of the studies published
recently, it was proposed that Klf4 negatively regulated
IL-1b production in murine macrophage cell line by directly
interacting with its promoter elements (Liu et al. 2012). To
find out if Klf4 negatively regulated IL-1b expression, we
measured IL-1b mRNA in Klf4 knockdown conditions. In
contrast, we found that upon Klf4 knockdown, IL-1b mRNA
levels reduced significantly over that of external IL-1b
treatment (Fig. 7c). Furthermore, ChIP analysis of IL-1b
promoter using Klf4 antibody confirmed that Klf4 directly
interacted with IL-1b promoter element (Fig. 7d).
Discussion
In this study, we investigated the role played by Klf4 in
regulating inflammatory processes in microglia upon IL-1b
stimulation. We show that microglia and not astrocytes or
neurons exhibit increased levels of Klf4 in response to IL-1b
in vivo. In vitro studies have shown that the levels of Klf4 did
not increase after 1 h of IL-1b stimulation of microglia,
which may define its role in early gene response. Our studies
show that Klf4 plays a crucial role for the up-regulation of
Cox-2 in microglia in response to IL-1b, an observation
similar to our findings from previous studies on LPS.
Another interesting finding of our study is the negative
regulation of iNOS by Klf4, which is in contrast to studies
that have shown that LPS and IL-1b strongly induce iNOS
expression in different cell types (Tsujino et al. 1994;
Kaushik et al. 2010). However, according to a study,
stimulation of BV-2 microglia with higher doses of IL-1b
Fig. 5 Inducible nitric oxide synthase
(iNOS) expression is negatively regulated
by Kr€uppel like factor-4 (Klf4). (a)
Immunoblot analysis of iNOS from total
cellular extracts of IL-1b treated BV-2 cells
at different time points. (b) Graph showing
qRT-PCR analysis of iNOS mRNA at
different time points in response to IL-1b,
and represents fold change over control. (c)
qRT-PCR analysis of iNOS transcript levels
from IL-1b stimulated microglia in siKlf4 and
scRNA transfected and mock-treated
conditions. Graph represents fold change
in Klf4 mRNA levels in treated conditions
over control. (d) iNOS protein levels from
IL-1b stimulated microglia in siKlf4 and
scRNA transfected and mock-treated
conditions. Values were normalized to
b-actin. Data represent mean  SEM from
three independent experiments. #, ##
Statistical difference with respect to IL-1b
treated condition (#p < 0.05; ##p < 0.01).
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was unable to induce iNOS activity as measured by nitric
oxide (NO) production even after 24 h of stimulation (Kim
et al. 2006). Similar observations were made by Ryu et al.,
who report that IL-1b does not induce iNOS expression and
subsequent NO production in macrophages (Ryu et al.
2000). In the light of the role played by Klf4 in response
to LPS, the current data present contrasting observation and
emphasize on the pleiotropic properties of Klf4 as a
transcription factor.
Furthermore, the finding that PI3K/Akt pathway is
involved in Klf4 mediated iNOS regulation in response to
IL-1b, in part, reinforces the immunomodulatory role of
PI3K/Akt pathway. Our study also revisited the production of
endogenous IL-1b in the light of Klf4 regulation. According
to a study on mouse macrophages, NO produced by iNOS
activity can down-regulate the endogenous production of IL-
1b suggesting that IL-1b gene expression may be controlled
in a feedback fashion (Obermeier et al. 1999). In support of
this finding, we found that during earlier time points in
response to IL-1b, endogenous IL-1b levels were robustly
elevated in culture supernatants. It is already known that
NF-jB plays a significant role in production of pro-
IL-1b (Mariathasan andMonack 2007), and since knockdown
of Klf4 resulted in decreased pro-IL-1b mRNA, we hypoth-
esize that Klf4 may be another crucial factor involved in the
production of IL-1b by binding to its promoter elements.
Furthermore, in accordance with the existing literature, our
studies show that the levels MCP-1 and IL-6 were found to be
significantly increased in response to IL-1b in BV-2 microg-
lial cells. However, it is interesting to note that the cytokine
levels in response to IL-1b are significantly less when
compared to LPS stimulated microglia (Kaushik et al. 2010).
Similar observations were made by Sheng et al. in their
studies when NO production in BV-2 cells was found to be
lower in response to a mixture of Tumor necrosis factor
(TNF)-a, IL-1b and IFN-c cytokines when compared with
LPS + IFN-c treatment condition (Sheng et al. 2011), sug-
gesting that cytokines may have immunomodulatory proper-
ties. In addition, a role of Klf4 is established in regulating the
expression of these cyto-chemokines in response to IL-1b. It
has already been shown that Klf4 interacts with p65 in our
previous studies in response to LPS (Kaushik et al. 2010),
therefore, in response to IL-1b, whether the two transcription
factors interact with each other, requires further investigation.
The schematic representation of our key observations and
hypotheses is outlined in Fig. 7e.
Fig. 6 Kr€uppel like factor-4 (Klf4)
negatively regulates inducible nitric oxide
synthase (iNOS) expression by down-
regulating its promoter activity. (a)
Immunoblot analysis for the expression
levels of iNOS and Klf4 upon Klf4 over-
expression in BV-2 cells. Graph represents
relative expression of iNOS and Klf4 in
different conditions with respect to LacZ
alone transfected cells. (b) Luciferase
activity measured in iNOS/pGL2
transfected cells co-transfected with either
K-10 or LacZ in unstimulated BV-2 cells and
after 3 h of IL-1b treatment. (c) Luciferase
activity of iNOS promoter from BV-2 and
transfected with either iNOS/pGL2 or
212ΔiNOS/pGL2 in presence or absence
of IL-1b. While protein levels were
normalized to b-actin, arbitrary luciferase
units were normalized to amount (lg) of
protein present in the samples. Data
represent mean  SEM from three
independent experiments. **, Statistical
difference with respect to mock-treated
condition (** p < 0.01). #, ## Statistical
difference with respect to IL-1b treated
condition in LacZ transfected cells
(#p < 0.05; ##p < 0.01).
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In summary, the premise for an inflammatory role of Klf4
in microglia is encouraged by current observations docu-
menting Klf4 up-regulation and subsequent orchestration of
inflammatory genes in response to IL-1b. Although, detailed
studies are further required to understand the implications
underlying our findings, our study reveals a potential
molecular target for the development of therapeutic agents
for the management of inflammatory conditions of CNS.
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Figure S3. Klf4 is required for MCP-1 and IL-6 production in
microglia.
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